Patents by Inventor Melissa Fleury

Melissa Fleury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neprilysin inhibitors
    Patent number: 11261197
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: March 1, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
  • Crystalline (2S,4R)-5-(5?-chloro-2?-fluoro-[1,1?-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
    Patent number: 11230536
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: January 25, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi
  • (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID
    Publication number: 20210401808
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • Neprilysin inhibitors
    Patent number: 11174219
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11130759
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: IDEAYA BIOSCIENCE, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • Neprilysin inhibitors
    Patent number: 11124502
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 21, 2021
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11110095
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 7, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11084798
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 10, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11046691
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: June 29, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • (2R,4R)-5-(5?-chloro-2?-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
    Patent number: 11033533
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • NEPRILYSIN INHIBITORS
    Publication number: 20210155576
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20210130351
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • NEPRILYSIN INHIBITORS
    Publication number: 20210079017
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 23, 2020
    Publication date: March 18, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
  • CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF
    Publication number: 20210061776
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 4, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi
  • NEPRILYSIN INHIBITORS
    Publication number: 20210059966
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 8, 2020
    Publication date: March 4, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20210024493
    Abstract: A method of treating a pulmonary disorder in a patient, comprising administering a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the pulmonary disorder is asthma or chronic obstructive pulmonary disorder.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric STANGELAND, Richard D. WILSON, Rose YEN
  • Diamide compounds having muscarinic receptor antagonist and ?2 adrenergic receptor agonist activity
    Patent number: 10836744
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: November 17, 2020
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • Neprilysin inhibitors
    Patent number: 10829438
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: November 10, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • NEPRILYSIN INHIBITORS
    Publication number: 20200283422
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: January 10, 2020
    Publication date: September 10, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID
    Publication number: 20200281900
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Application
    Filed: December 16, 2019
    Publication date: September 10, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta